BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1018 related articles for article (PubMed ID: 24559611)

  • 1. Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival.
    Dieterich M; Hartwig F; Stubert J; Klöcking S; Kundt G; Stengel B; Reimer T; Gerber B
    Breast; 2014 Aug; 23(4):346-51. PubMed ID: 24559611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Grade of ductal carcinoma in situ accompanying infiltrating ductal carcinoma as an independent prognostic factor.
    Kim JY; Han W; Moon HG; Park IA; Ahn SK; Kim J; Lee JW; Kim T; Kim MK; Noh DY
    Clin Breast Cancer; 2013 Oct; 13(5):385-91. PubMed ID: 23870857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
    Choi YJ; Shin YD; Song YJ
    World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extent of ductal carcinoma in situ within and surrounding invasive primary breast carcinoma.
    Crombie N; Rampaul RS; Pinder SE; Elston CW; Robertson JF; Ellis IO
    Br J Surg; 2001 Oct; 88(10):1324-9. PubMed ID: 11578285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
    Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
    Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast.
    de Roos MA; de Bock GH; de Vries J; van der Vegt B; Wesseling J
    J Surg Res; 2007 Jun; 140(1):109-14. PubMed ID: 17291532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microinvasive breast carcinoma: clinicopathologic analysis of a single institution experience.
    Padmore RF; Fowble B; Hoffman J; Rosser C; Hanlon A; Patchefsky AS
    Cancer; 2000 Mar; 88(6):1403-9. PubMed ID: 10717623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.
    Di Saverio S; Catena F; Santini D; Ansaloni L; Fogacci T; Mignani S; Leone A; Gazzotti F; Gagliardi S; De Cataldis A; Taffurelli M
    Breast Cancer Res Treat; 2008 Jun; 109(3):405-16. PubMed ID: 17687650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there a low-grade precursor pathway in breast cancer?
    King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
    Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes.
    Goh CW; Wu J; Ding S; Lin C; Chen X; Huang O; Chen W; Li Y; Shen K; Zhu L
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1877-1886. PubMed ID: 31089799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The target for statins, HMG-CoA reductase, is expressed in ductal carcinoma-in situ and may predict patient response to radiotherapy.
    Butt S; Butt T; Jirström K; Hartman L; Amini RM; Zhou W; Wärnberg F; Borgquist S
    Ann Surg Oncol; 2014 Sep; 21(9):2911-9. PubMed ID: 24777857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lobular breast cancer: same survival and local control compared with ductal cancer, but should both be treated the same way? analysis of an institutional database over a 10-year period.
    Fortunato L; Mascaro A; Poccia I; Andrich R; Amini M; Costarelli L; Cortese G; Farina M; Vitelli C
    Ann Surg Oncol; 2012 Apr; 19(4):1107-14. PubMed ID: 21913022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic differences between pure ductal carcinoma in situ of the breast and that associated with invasive disease: a calibrated aCGH study.
    Iakovlev VV; Arneson NC; Wong V; Wang C; Leung S; Iakovleva G; Warren K; Pintilie M; Done SJ
    Clin Cancer Res; 2008 Jul; 14(14):4446-54. PubMed ID: 18628458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extensive pure ductal carcinoma in situ of the breast: identification of predictors of associated infiltrating carcinoma and lymph node metastasis before immediate reconstructive surgery.
    Guillot E; Vaysse C; Goetgeluck J; Falcou MC; Couturaud B; Fitoussi A; Fourchotte V; Laki F; Malhaire C; Sigal-Zafrani B; Sastre-Garau X; Bollet MA; Mosseri V; Reyal F
    Breast; 2014 Apr; 23(2):97-103. PubMed ID: 24388733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should ductal carcinoma-in-situ (DCIS) be removed from the ASTRO consensus panel cautionary group for off-protocol use of accelerated partial breast irradiation (APBI)? A pooled analysis of outcomes for 300 patients with DCIS treated with APBI.
    Vicini F; Shah C; Ben Wilkinson J; Keisch M; Beitsch P; Lyden M
    Ann Surg Oncol; 2013 Apr; 20(4):1275-81. PubMed ID: 23054123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
    von Minckwitz G; Darb-Esfahani S; Loibl S; Huober J; Tesch H; Solbach C; Holms F; Eidtmann H; Dietrich K; Just M; Clemens MR; Hanusch C; Schrader I; Henschen S; Hoffmann G; Tiemann K; Diebold K; Untch M; Denkert C
    Breast Cancer Res Treat; 2012 Apr; 132(3):863-70. PubMed ID: 21667238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cytoplasmic expression of aquaporin-1 in breast cancer cells and its relationship with clinicopathological characteristics and prognosis].
    Zhang B; Liu FF; Ma YJ; Gu F
    Zhonghua Zhong Liu Za Zhi; 2013 Dec; 35(12):904-9. PubMed ID: 24506959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local recurrences after conservative treatment of ductal carcinoma-in-situ of the breast without radiotherapy: the effect of age.
    Schouten van der Velden AP; Peeters PH; Koot VC; Hennipman A
    Ann Surg Oncol; 2006 Jul; 13(7):990-8. PubMed ID: 16788762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microcalcifications in 1657 Patients with Pure Ductal Carcinoma in Situ of the Breast: Correlation with Clinical, Histopathologic, Biologic Features, and Local Recurrence.
    Rauch GM; Hobbs BP; Kuerer HM; Scoggins ME; Benveniste AP; Park YM; Caudle AS; Fox PS; Smith BD; Adrada BE; Krishnamurthy S; Yang WT
    Ann Surg Oncol; 2016 Feb; 23(2):482-9. PubMed ID: 26416712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
    Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.